Cryoablation Devices have emerged as an effective medical device for the treatment of various cancers and arrhythmias

 

Cryoablation Devices

Single-use cryoablation devices are designed for treating single tumor sites with great flexibility and portability. These devices can be easily integrated into existing clinical work or can be used in on-site treatment facilities. Single-use devices provide excellent tumor control and management for lung cancers, skin cancers, pancreatic cancer, ovarian cancer, leukemia, bone cancers, head and neck cancers, cervical cancers, and other solid tumors. Localized cryoablation is a process of injecting high-temperature gas in the direction of the tumor to destroy the affected tissues. This process results in the CO2 injection, which aids in localizing the tumor and preventing its spread to other areas.

A local progression of the disease is prevented because the heat generated damages tumor cells and prevents them from replicating. This therapy has good control over metastasis. Its effects are most effective during the first one to three weeks of treatment and the post-operative symptoms are also relieved. Risks of the procedure include allergic reactions, which include signs and symptoms such as swelling, redness, itching, peeling, and cracking. In case of hypothermia, seizures and fever may occur. Patients who have had no prior surgery and those with an increased risk of developing complications are at a higher risk of complications.

When the procedure is performed under general anesthesia, complications are rare. However, if the inoperable stage is reached before the medication dose has reached the targeted site, there is a high risk of mortality. A very common complication after cryoablation is diarrhea. Some patients develop a profusely watery discharge. A less common complication after anesthesia is an infection of the treated area or of the peritoneum or the abdomen. A very rare complication, however, is death from ventricular tachycardia or cardiomyopathy caused by oxygen deprivation. Recently, in June 2021, Medtronic received the U.S. Food and Drug Administration (FDA) approval for its Arctic Front Family of Cardiac Cryoablation catheters to treat recurrent symptomatic paroxysmal atrial fibrillation (AF).


Comments

Popular posts from this blog

Light Linear Alpha Olefins Are Produces through Oligomerization of Ethylene and by Fischer-Tropsch Synthesis

Cervical Cancer Diagnostic Tests have become highly sophisticated with accurate diagnosis for effective treatment

Beta Glucan-based products have been shown to be effective in lowering cholesterol and preventing heart disease